You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Oligonucleotide Inhibition for cardiac regeneration in Ischemia

    SBC: JAAN BIOTHERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration of heart function compromise of contractile reserve ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. NOVO-118 as a therapeutic to promote remyelination in in vivo models of MS

    SBC: NOVORON BIOSCIENCE INC            Topic: NINDS

    7. Project Summary Multiple sclerosis (MS) is a neurodegenerative disease in which myelin of the central nervous system (CNS) is destroyed by a self-reactive immune response. This demyelination is accompanied by the death of the myelinating cells themselves, the oligodendrocytes. Repeated bouts of demyelination leave the denuded CNS neurons vulnerable to degradation and is the major cause of neuro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Treatment for Traumatic Brain Injury

    SBC: Epigen Biosciences, Inc.            Topic: 101

    SUMMARY Traumatic brain injury TBI is a leading contributor to death and disability in the USA yet widely effective treatments remain elusive and except for a lengthy program of rehabilitation no effective treatment for TBI is available Therefore there is a critical need in new therapeutic approaches which can maximally preserve brain tissue and facilitate functional recovery after TBI In ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel therapy for Fragile X syndrome

    SBC: Epigen Biosciences, Inc.            Topic: 101

    PROJECT SUMMARY Fragile X syndromeFXSis the most common inheritable form of cognitive impairment and the leading known genetic cause of autismFXS is caused by the loss of expression of the fragile X mental retardation proteinFMRPA major challenge for FXS research is to develop treatment strategies that improve the intellectual capabilities of patientsDysregulated protein synthesis is widely accept ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Novel noninvasive diagnostic technology for dynamic imaging of mitochondrial bioenergetics in breast cancer patients

    SBC: ROBIN MEDICAL INC            Topic: 102

    Summary Breast cancer is the second most common and the major cause of cancer related death of women in the USA The last decade has witnessed major advancement of therapeutic drugs and tools while noninvasive diagnostic imaging tools to measure interventions received much less attention Currently the mainstay of noninvasive imaging in breast cancer relies primarily on anatomic imaging Metabol ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Novel monoclonal antibody for single dose treatment of acute CNS injury

    SBC: Oncosynergy, Inc.            Topic: 999

    PROJECT SUMMARY Traumatic brain injury (TBI) represents a significant societal and economic impact. To date, there are no FDA- approved pharmacotherapies to prevent or reverse TBI. The standard of care in an emergency setting focuses first on stabilizing the patient and secondly on management of cerebral hemodynamics. The patient may undergo surgery to remove hematomas, repair skull fractures, and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Mixed-mode TCAD-Commercial PDK Integrated Flow for Radiation Hardening By Design

    SBC: CFD RESEARCH CORPORATION            Topic: DTRA16A003

    Cost-effective application of advanced commercial electronics technologies in DoD space systems requires early development of radiation-hardened-by-design (RHBD) techniques, and use of simulations is critical to the efficiency of this process. CFDRC has developed an integrated, mixed-mode simulation approach allowing their NanoTCAD device physics simulator to interface with commercial circuit simu ...

    STTR Phase I 2017 Department of DefenseDefense Threat Reduction Agency
  8. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder

    SBC: BIOMEDICAL DEVELOPMENT CORP            Topic: 103

    DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Next Generation Regenerative Therapy with Pim Enhanced Cardiac Progenitor Cells

    SBC: CardioCreate, Inc.            Topic: NHLBI

    PROJECT SUMMARY Myocardial regenerative therapy is poised to revolutionize the way heart failure is treated but further improvements and enhanced products are needed to make this therapy truly safe and efficacious Our company CardioCreate Inc has pioneered the use of genetic engineering to enhance the regenerative potential of human Cardiac Progenitor Cells CPCs intended for autologous the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government